CDK7/12/13 inhibition targets an oscillating leukemia stem cell network and synergizes with venetoclax in acute myeloid leukemia.

EMBO Mol Med · 2022 · PMC8988201 · PMID 35253392

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

ShGPR56 weak only showed a trend towards lower engraftment at four weeks and had no disadvantage in overall human CD45 + GFP + engraftment at later time points.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.